Cargando…

Management of cognitive and negative symptoms in schizophrenia

Currently available antipsychotics provide only modest benefit in managing the cognitive and negative symptoms of schizophrenia even though these symptoms are often the most impairing in patients' daily lives. Certain antipsychotics may have slight benefits over others, and several nonpharmacol...

Descripción completa

Detalles Bibliográficos
Autor principal: Maroney, Megan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Psychiatric Pharmacists 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645289/
https://www.ncbi.nlm.nih.gov/pubmed/36405508
http://dx.doi.org/10.9740/mhc.2022.10.282
_version_ 1784826934232875008
author Maroney, Megan
author_facet Maroney, Megan
author_sort Maroney, Megan
collection PubMed
description Currently available antipsychotics provide only modest benefit in managing the cognitive and negative symptoms of schizophrenia even though these symptoms are often the most impairing in patients' daily lives. Certain antipsychotics may have slight benefits over others, and several nonpharmacologic and pharmacologic adjunctive treatments have been evaluated in recent clinical trials. Recently published meta-analyses and clinical studies of such treatments are reviewed. Potential strategies to manage cognitive and negative symptoms, including deprescribing of medications that may exacerbate these symptoms, are described using theoretical case examples.
format Online
Article
Text
id pubmed-9645289
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association of Psychiatric Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-96452892022-11-18 Management of cognitive and negative symptoms in schizophrenia Maroney, Megan Ment Health Clin Psychopharmacology Pearls Currently available antipsychotics provide only modest benefit in managing the cognitive and negative symptoms of schizophrenia even though these symptoms are often the most impairing in patients' daily lives. Certain antipsychotics may have slight benefits over others, and several nonpharmacologic and pharmacologic adjunctive treatments have been evaluated in recent clinical trials. Recently published meta-analyses and clinical studies of such treatments are reviewed. Potential strategies to manage cognitive and negative symptoms, including deprescribing of medications that may exacerbate these symptoms, are described using theoretical case examples. American Association of Psychiatric Pharmacists 2022-11-03 /pmc/articles/PMC9645289/ /pubmed/36405508 http://dx.doi.org/10.9740/mhc.2022.10.282 Text en © 2022 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Psychopharmacology Pearls
Maroney, Megan
Management of cognitive and negative symptoms in schizophrenia
title Management of cognitive and negative symptoms in schizophrenia
title_full Management of cognitive and negative symptoms in schizophrenia
title_fullStr Management of cognitive and negative symptoms in schizophrenia
title_full_unstemmed Management of cognitive and negative symptoms in schizophrenia
title_short Management of cognitive and negative symptoms in schizophrenia
title_sort management of cognitive and negative symptoms in schizophrenia
topic Psychopharmacology Pearls
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645289/
https://www.ncbi.nlm.nih.gov/pubmed/36405508
http://dx.doi.org/10.9740/mhc.2022.10.282
work_keys_str_mv AT maroneymegan managementofcognitiveandnegativesymptomsinschizophrenia